Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1264-1268

  Distler, Alfiya ^a   Lang, Veronika ^a   Del Vecchio, Tina ^a   Huang, Jingang ^a   Zhang, Yun ^a   Beyer, Christian ^a   Lin, Neng Yu ^a   Palumbo Zerr, Katrin ^a   Distler, Oliver ^b   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; BIOLOGICAL MARKER; BLEOMYCIN; COLLAGEN; CYCLOPAMINE; GAMMA SECRETASE INHIBITOR; HYDROXYPROLINE; ICG 001; LGR5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; HEDGEHOG SIGNALING; INTESTINAL STEM CELL; LOW DRUG DOSE; MONOTHERAPY; MOUSE; MYOFIBROBLAST; NONHUMAN; NOTCH SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN FIBROSIS; STEM CELL; WNT SIGNALING PATHWAY;

FIBROBLASTS; SYSTEMIC SCLEROSIS; TREATMENT;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLEOMYCIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBROSIS; HEDGEHOG PROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINONES; RECEPTORS, NOTCH; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; VERATRUM ALKALOIDS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84899925204     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204221     Document Type: Article

References (20)

1. Dale J, Alcorn N, Capell H, et al. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol 2007;3:450-8; quiz, following 478. (Pubitemid 47193551)
2. Benza RL, Park MH, Keogh A, et al. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant 2007;26: 437-46. (Pubitemid 46602007)
3. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun 2012;3:735.
4. Bergmann C, Akhmetshina A, Dees C, et al. Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 2011;70: 2191-8.
5. Beyer C, Schramm A, Akhmetshina A, et al. beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012;71: 761-7.
6. Dees C, Tomcik M, Zerr P, et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011;70: 1304-10.
7. Dees C, Zerr P, Tomcik M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011;63: 1396-404.
8. Distler A, Deloch L, Huang J, et al. Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Ann Rheum Dis 2013;72: 1575-80.
9. Horn A, Kireva T, Palumbo-Zerr K, et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis 2012;71: 785-9.
10. Horn A, Palumbo K, Cordazzo C, et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 2012;64: 2724-33.
11. Kavian N, Servettaz A, Mongaret C, et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum 2010;62: 3477-87.
12. Wei J, Fang F, Lam AP, et al. Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012;64: 2734-45.
13. Wei J, Melichian D, Komura K, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum 2011;63: 1707-17.
14. Bayle J, Fitch J, Jacobsen K, et al. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2008;128: 871-81. (Pubitemid 351374297)
15. Zerr P, Palumbo-Zerr K, Distler A, et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 2012;120: 2909-17.
16. Beyer C, Reichert H, Akan H, et al. Blockade of canonical Wnt signaling ameliorates experimental dermal fibrosis. Ann Rheum Dis 2013;72: 1255-8.
17. Yeung TM, Chia LA, Kosinski CM, et al. Regulation of self-renewal and differentiation by the intestinal stem cell niche. Cell Mol Life Sci 2011;68: 2513-23.
18. Beyer C, Dees C, Distler JH. Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. Arch Dermatol Res 2013;305: 1-8.
19. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208: 961-72.
20. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449: 1003-7. (Pubitemid 350014593)